Back to mobile site

AbbVie (ABBV): The Upside To IPR Loss - BMO

May 17, 2017 6:18 AM EDT Send to a Friend
BMO Capital analyst, Alex Arfei, reiterated his Market Perform rating on shares of Abbvie (NYSE: ABBV) despite the invalidation of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login